Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward

You may also be interested in...



As Clinical Trials Boom In India, Patient Recruitment Firm D. Anderson Plans To Establish Direct Presence

MUMBAI - U.S. based D. Anderson & Co, a provider of global patient recruitment and retention services for clinical trials, is planning to establish a direct presence in India

As Clinical Trials Boom In India, Patient Recruitment Firm D. Anderson Plans To Establish Direct Presence

MUMBAI - U.S. based D. Anderson & Co, a provider of global patient recruitment and retention services for clinical trials, is planning to establish a direct presence in India

Drug Controller General Of India, Surinder Singh, On India’s Regulatory Overhaul: An Interview With PharmAsia News

Singh recounts steps toward Indian first-in-human drug trials.

Related Content

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel